Fresenius Kabi rolls out generic Torisel
Fresenius Kabi's generic Torisel is indicated to treat renal cell carcinoma.
A new generic treatment for advanced renal cell carcinoma is now available. Fresenius Kabi is offering temsirolimus injection.
The medication is the generic of Pfizer’s Torisel.
Fresenius Kabi's product is supplied as a kit including one vial of 25 mg/mL temsirolimus solution and one vial of diluent.
“Fresenius Kabi is committed to expanding affordable treatment options for patients,” said John Ducker, president and CEO of Fresenius Kabi USA. “The addition of Temsirolimus is the most recent example of our development program and deep expertise in oncology medicines. Fresenius Kabi is pleased to continue to develop high-quality therapies that clinicians can deliver knowing they are safe, efficacious and accessible for their patients.”